NS 2330
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for NS 2330, covering 2013-10-29 to 2013-10-29. Get the full timeline:
Most recent: Clinical Trial Update: A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE) [Phase 2]